Mr. Thomas Smeenk reports

HEMOSTEMIX'S EXPANDS ITS MARKETING TEAM FOCUSED ON SALES IN FLORIDA

Hemostemix Inc. has appointed a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell in Florida to podiatrist and vascular surgeons to treat PAD and CLTI and to cardiologists to treat angina, ischemic cardiomyopathy, dilated cardiomyopathy and congestive heart failure.

The additions to the leadership team are top-tier talent with a proven record of success in the biopharmaceutical industry:

• Croom Lawrence, chief commercial officer: With over 25 years of biotech commercial launch experience, Mr. Lawrence is a veteran in building high performing commercial teams and launching breakthrough therapies. He has supported 15-plus blockbuster launches including global platform brands with multiple indications from Humira ($8-billion), Rinvoq ($6-billion) to Dupixent ($3-billion). He has generated hundreds of millions in return on marketing investment for Fortune 100 biotech clients, including Merck, BMS, Amgen and Pfizer/Wyeth. He has recently been recognized with a PM360 innovation award in 2025 for a cognitive testing start-up, Acurist.AI.
• Sana Farooqui, fractional chief marketing officer: A seasoned digital strategist and marketing professional, Ms. Farooqui will lead the company's digital and social marketing efforts. She will direct messaging across key channels of influence to physicians, patients and investors, ensuring the VesCell message is impactful, compliant and aligned with Hemostemix's mission.
• Bob Branch, fractional vice-president, digital marketing and media: With 20-plus years of full-funnel medical marketing and media experience from top health communications agencies, Mr. Branch will be instrumental in developing and delivering insight-led, omnichannel go-to-market strategies. He has deep experience working with industry leaders like AbbVie, Novartis and Merck on dozens of brands in cardiovascular, neurology and dermatology, making him an ideal fit to drive media strategies that connect key audiences with VesCell's benefits.

A new chance to live better, longer

Under Florida's right-to-try statute (SB 1768), physicians -- including podiatrists, cardiologists and all specialists treating pain and no-option patients suffering from PAD, CLTI, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy and congestive heart failure -- can offer VesCell, Hemostemix's patented ACP-01 therapy, to qualifying patients, following informed consent.

• Podiatrists and vascular surgeons -- improve limb circulation and prevent amputation: In three published trials, including phase 2, VesCell generated new circulation to restore blood flow, healed ulcers and reduced the need for amputation.
• Cardiologists -- restore cardiac function: In four published studies of 24, 41, 106 and 53 subjects, VesCell increased ejection fraction, reduced severe angina, improved exercise capacity and improved quality of life in patients suffering from angina, ischemic and non-ischemic dilated cardiomyopathy, respectively.
• (Future) neurologists -- address vascular dementia: Early human results suggest persistent cognitive benefits in vascular dementia for over 10 years in one patient treated with VesCell.

"Hemostemix's new outreach team is tasked with ensuring every eligible Florida practitioner knows the science, the law and how VesCell works for their patients. This team's collective experience of translating VesCell published outcomes into a clear, compelling messaging for a variety of audiences enables us to reach these cohorts of patients who suffer in pain," stated Thomas Smeenk, chief executive officer.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects, and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, UBC and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.